CD19-targeted CAR-T cells
Sponsors
Sinobioway Cell Therapy Co., Ltd., Qingdao Central Hospital
Conditions
LeukemiaLeukemia, B-CellLymphomaLymphoma, B-CellMinimal Disease, Residual
Unknown Phase
Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
NCT02728882
Start: 2015-07-02End: 2019-07-31Target: 24Updated: 2017-03-23
Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia
NCT02735291
Start: 2015-11-30End: 2025-12-31Updated: 2020-07-15
CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma
NCT03488160
Start: 2018-04-10End: 2019-04-20Target: 6Updated: 2018-04-10
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation
NCT03564977
Start: 2018-07-15End: 2020-06-15Target: 20Updated: 2018-07-02